表紙
市場調查報告書

年齡相關黃斑部病變:至2028年的流行病學預測

Age-Related Macular Degeneration: Epidemiology Forecast to 2028

出版商 GlobalData 商品編碼 312373
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
年齡相關黃斑部病變:至2028年的流行病學預測 Age-Related Macular Degeneration: Epidemiology Forecast to 2028
出版日期: 2020年04月01日內容資訊: 英文 46 Pages
簡介

老年性黃斑部病變(AMD),是由於在網膜負責中心視野,黃斑的階段性劣化所引起的進行性眼科疾病。AMD,成為在老年人之間引起顯著的不可逆性的視力降低的最常見原因。AMD,分類為初期AMD、中期AMD、後期AMD3個階段。2018年主要9個市場上50歲以上的男女總合的AMD的患病數是9,724萬3,455件。中國的整體患病人數為2,091萬4,288人,澳洲以77萬8,580人病例數較低。主要9個市場上AMD的整體患病人數,預計2028年增加到1億1,492萬8,241件。

本報告提供全球主要7個國家的老年性黃斑部病變(AMD)調查分析,疾病的背景,危險因素和合併症,全球趨勢,流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 老年性黃斑部病變:摘要整理

第3章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球歷史的趨勢
  • 預測手法
    • 出處
    • 預測的前提條件與方法
    • AMD,早期AMD,後期AMD,後期乾AMD,及後期濕AMD的盛行率的總合
    • 各一側性的AMD的盛行率的總合
    • 後期乾型AMD繼發性地理萎縮的全患病案例的全患病案例
    • AMD,早期AMD,後期AMD,後期乾AMD,及後期濕AMD的確診的患病案例
  • AMD的流行病學預測,2018-2028
    • AMD流行的案例的總合
    • AMD的各年齡的全患病案例
    • AMD的性別固有的盛行率的高的病例
    • 各一側性的AMD的盛行率的總合
    • 初期的AMD的一般案例
    • AMD後期的流行案例的總數
    • 後期乾AMD的盛行率的總合
    • 後期濕型AMD的流行案例
    • 後期乾AMD繼發性地理萎縮的全患病案例
    • AMD的確診的流行的案例
    • AMD的各年齡診斷診斷患病案例
    • AMD的性特異性診斷患病案例
    • 早期AMD的確診的患病案例
    • AMD後期的確診的患病案例
    • 後期乾AMD的確診的患病案例
    • 後期濕性AMD的確診的患病案例
    • 後期乾AMD繼發性地理萎縮的確診的患病案例
  • 討論
    • 流行病學預測的洞察
    • 分析的限制
    • 分析的優勢

第4章 附錄

  • 參考文獻
  • 1次調查
  • 關於作者
  • 關於GlobalData
  • 諮詢方式
  • 免責聲明

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER237-20

Age-related macular degeneration (AMD) is a progressive eye condition that is characterized by the gradual deterioration of the macula, which is the area of the retina responsible for central vision. AMD is the most common cause of significant irreversible vision loss among the elderly (National Eye Institution, 2019). AMD is classified into three stages: early AMD, intermediate AMD, and late AMD.

Late AMD is the advanced stage of AMD, which is characterized by the presence of late dry AMD (geographic atrophy) or late wet (neovascular or exudative) AMD (van Leeuwen et al., 2003; Coleman et al., 2008; Korb et al., 2014). According to a meta-analysis of studies conducted before May 2013, the global prevalence of AMD was reported to be 8.69% among adults ages 45-85 years, but the country-specific prevalence can be as high as 30-40% (Augood et al., 2006; Wong et al., 2014). In addition to the high prevalence of the condition, AMD is also associated with severe disability and has a major impact on the quality of life and emotional well-being of an affected individual (Hassell, 2006).

In 2018, there were 97,243,455 total prevalent cases of AMD in men and women combined, ages 50 years and older, in the 9MM. China accounted for the majority of these cases with 20,914,288 total prevalent cases, while Australia accounted for the fewest cases with 778,580 cases in 2018. GlobalData epidemiologists forecast an increase in the total prevalent cases of AMD to 114,928,241 cases in 2028 in the 9MM at an Annual Growth Rate (AGR) of 1.82% during the forecast period.

Scope

  • The Age-Related Macular Degeneration report provides an overview of the risk factors, comorbidities, and the global and historical trends for AMD in the nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, Australia, and China).
  • The report also includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of AMD, each segmented into early AMD and late AMD and broken down by sex and age (limited to age 50 years and older).
  • The total and diagnosed prevalent cases of late AMD are further segmented into late dry and late wet AMD.
  • The total prevalent cases of AMD are also segmented by laterality (single eye and both eyes). The report also includes the total prevalent cases and diagnosed prevalent cases of geographic atrophy secondary to late dry AMD in these markets.
  • The AMD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.

Reasons to Buy

The AMD Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global AMD market.
  • Quantify patient populations in the global AMD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for AMD therapeutics in each of the markets covered.
  • Understand magnitude of AMD by stages and laterality.

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Age-Related Macular Degeneration: Executive Summary

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods
    • 3.4.3 Total Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, and Late Wet AMD
    • 3.4.4 Total Prevalent Cases of AMD by Laterality
    • 3.4.5 Total Prevalent Cases of Total Prevalent Cases of Geographic Atrophy Secondary to Late Dry AMD
    • 3.4.6 Diagnosed Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, and Late Wet AMD
  • 3.5 Epidemiological Forecast for AMD, 2018-2028
    • 3.5.1 Total Prevalent Cases of AMD
    • 3.5.2 Age-Specific Total Prevalent Cases of AMD
    • 3.5.3 Sex-Specific Total Prevalent Cases of AMD
    • 3.5.4 Total Prevalent Cases of AMD by Laterality
    • 3.5.5 Total Prevalent Cases of Early AMD
    • 3.5.6 Total Prevalent Cases of Late AMD
    • 3.5.7 Total Prevalent Cases of Late Dry AMD
    • 3.5.8 Total Prevalent Cases of Late Wet AMD
    • 3.5.9 Total Prevalent Cases of Geographic Atrophy Secondary to Late Dry AMD
    • 3.5.10 Diagnosed Prevalent Cases of AMD
    • 3.5.11 Age-Specific Diagnosed Prevalent Cases of AMD
    • 3.5.12 Sex-Specific Diagnosed Prevalent Cases of AMD
    • 3.5.13 Diagnosed Prevalent Cases of Early AMD
    • 3.5.14 Diagnosed Prevalent Cases of Late AMD
    • 3.5.15 Diagnosed Prevalent Cases of Late Dry AMD
    • 3.5.16 Diagnosed Prevalent Cases of Late Wet AMD
    • 3.5.17 Diagnosed Prevalent Cases of Geographic Atrophy Secondary to Late Dry AMD
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Limitations of the Analysis
    • 3.6.3 Strengths of the Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 Primary Research - Prescriber Survey
  • 4.3 About the Authors
    • 4.3.1 Epidemiologist
    • 4.3.2 Reviewers
    • 4.3.3 Global Director of Therapy Analysis and Epidemiology
    • 4.3.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.4 About GlobalData
  • 4.5 Contact Us
  • 4.6 Disclaimer

List of Tables

  • Table 1: Summary of Newly Added Data Types and Countries
  • Table 2: Risk Factors and Comorbidities for AMD
  • Table 3: High-Prescribing Physicians (KOL and non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: 9MM, Total Prevalent Cases of AMD, Both Sexes, Ages ≥50 Years, 2018 and 2028
  • Figure 2: 9MM, Diagnosed Prevalent Cases of AMD, Both Sexes, Ages ≥50 Years, 2018 and 2028
  • Figure 3: 9MM, Total Prevalence of AMD, Men and Women, Ages ≥50 Years, %, 2018
  • Figure 4: 9MM, Diagnosed Prevalence of AMD, Men and Women, Ages ≥50 Years, 2018
  • Figure 5: 9MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, and Late Wet AMD
  • Figure 6: 9MM, Sources Used to Forecast the Total Prevalent Cases of AMD by Laterality
  • Figure 7: 9MM, Sources Used to Forecast the Total Prevalent Cases of Geographic Atrophy Secondary to Late Dry AMD and Diagnosed Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, and Late Wet AMD
  • Figure 8: 9MM, Total Prevalent Cases of AMD, Both Sexes, Ages ≥50 Years, N, 2018
  • Figure 9: 9MM, Total Prevalent Cases of AMDby Age, Both Sexes, N, 2018
  • Figure 10: 9MM, Total Prevalent Cases of AMD, by Sex, Ages ≥50 Years, N, 2018
  • Figure 11: 9MM, Total Prevalent Cases of AMD by Laterality, Ages ≥50 Years, Both Sexes, N, 2018
  • Figure 12: 9MM, Total Prevalent Cases of Early AMD, Both Sexes, Ages ≥50 Years, N, 2018
  • Figure 13: 9MM, Total Prevalent Cases of Late AMD, Both Sexes, Ages ≥50 Years, N, 2018
  • Figure 14: 9MM, Total Prevalent Cases of Late Dry AMD, Both Sexes, Ages ≥50 Years, N, 2018
  • Figure 15: 9MM, Total Prevalent Cases of Late Wet AMD, Both Sexes, Ages ≥50 Years, N, 2018
  • Figure 16: 9MM, Total Prevalent Cases of Geographic Atrophy Secondary to Late Dry AMD, Both Sexes, Ages ≥50 Years, N, 2018
  • Figure 17: 9MM, Diagnosed Prevalent Cases of AMD, Both Sexes, Ages ≥50 Years, N, 2018
  • Figure 18: 9MM, Diagnosed Prevalent Cases of AMD by Age, Both Sexes, N, 2018
  • Figure 19: 9MM, Diagnosed Prevalent Cases of AMD, by Sex, Ages ≥50 Years, N, 2018
  • Figure 20: 9MM, Diagnosed Prevalent Cases of Early AMD, Both Sexes, Ages ≥50 Years, N, 2018
  • Figure 21: 9MM, Diagnosed Prevalent Cases of Late AMD, Both Sexes, Ages ≥50 Years, N, 2018
  • Figure 22: 9MM, Diagnosed Prevalent Cases of Late Dry AMD, Both Sexes, Ages ≥50 Years, N, 2018
  • Figure 23: 9MM, Diagnosed Prevalent Cases of Late Wet AMD, Both Sexes, Ages ≥50 Years, N, 2018
  • Figure 24: 9MM, Diagnosed Prevalent Cases of Geographic Atrophy Secondary to Late Dry AMD, Both Sexes, Ages ≥50 Years, N, 2018